Drug news
Janssen acquires GSK 2336805 for Hepatitis C
Janssen Pharmaceuticals, Inc. has announced the acquisition of the investigational compound GSK 2336805, an NS5a replication complex inhibitor in Phase II development for the treatment of chronic Hepatitis C, from an affiliate of GlaxoSmithKline plc. Janssen has acquired all rights to develop and commercialize GSK 2336805, including in combination with other drugs. A programme to develop GSK 2336805 with VX-135 has been cancelled.